Kenvue has completed a global agency review, appointing WPP and Publicis Groupe as its worldwide agency partners, according to a global report.
Under the new arrangement, WPP will lead creative and production across Kenvue’s portfolio in all channels and markets, excluding Neutrogena. Publicis Groupe will manage media, commerce, healthcare communications and technology services for all Kenvue brands, and will also handle creative and production for Neutrogena. Publicis already manages Kenvue’s media business in the Asia-Pacific region.
The review covered Kenvue’s global brand portfolio, including Tylenol, Listerine and Neutrogena. COMvergence estimates cited in the report put the company’s global media spend at about $1.35 billion in 2025.
The agency appointments come as Kenvue continues to manage issues affecting Tylenol. In 2025, the brand was the subject of public discussion after the Trump administration raised concerns about the use of acetaminophen during pregnancy. These claims were challenged by the medical community, and Kenvue maintained an evidence-based communications approach while legal proceedings progressed.
The review also follows leadership changes at the company. In October 2025, Kenvue appointed Jon Halvorson to a newly created role combining global marketing leadership and digital commerce strategy.
